Haemonetics Corporation (HAE) Financials

EPS

Hollow marker is the consensus estimate; filled is the reported figure, colored by beat or miss.

Revenue

Outlined bar is the consensus estimate; solid is reported.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
Q1 27	$1.08	$1.14	+5.6%	—	$339.4M	—
Q4 26	-$0.47	-$0.43	+8.5%	—	$346.4M	—
Q2 26	$1.11	$1.27	+14.4%	—	$327.3M	—
Q1 26	$1.02	$1.1	+7.8%	—	$321.4M	—
Q4 25	$1.22	$1.24	+1.6%	—	$330.6M	—
Q3 25	$1.17	$1.19	+1.7%	—	$348.5M	—
Q2 25	$1.07	$1.12	+4.7%	—	$345.5M	—
Q1 25	$1.01	$1.02	+1.0%	—	$336.2M	—
Q4 24	$0.89	$0.9	+1.1%	—	$343.3M	—
Q3 24	$0.94	$1.04	+10.6%	—	$336.3M	—
Q2 24	$0.89	$0.99	+11.2%	—	$318.2M	—
Q1 24	$0.73	$1.05	+43.8%	—	$311.3M	—
Q4 23	$0.7	$0.77	+10.0%	—	$304.4M	—
Q3 23	$0.82	$0.85	+3.7%	—	$305.3M	—
Q2 23	$0.67	$0.83	+23.9%	—	$297.5M	—
Q1 23	$0.51	$0.58	+13.7%	—	$261.5M	—

EPS

Reported per-share earnings by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Revenue

Reported revenue by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
FY26	—	$2.06	—	—	$1.3B	—
FY25	—	$3.33	—	—	$1.4B	—
FY24	—	$2.32	—	—	$1.3B	—
FY23	—	$2.27	—	—	$1.2B

Total revenue

Reported revenue per period; the line is the change from the same period a year earlier, on its own left axis.

Period	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	$886.1M	$903.9M	$967.6M	$988.5M	$870.5M	$993.2M	$1.2B	$1.3B	$1.4B	$1.3B
YoY change	-2.5%	+2.01%	+7.04%	+2.16%	-11.9%	+14.1%	+17.7%	+12%	+3.95%	-1.97%

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	886.1M	903.9M	967.6M	988.5M	870.5M	993.2M	1.2B	1.3B	1.4B	1.3B
Cost of revenue	507.6M	492M	550M	504M	472.6M	487.7M	553.6M	617.5M	611.9M	546.4M
Gross profit	378.5M	411.9M	417.5M	484.5M	397.8M	505.5M	615.1M	691.5M	749M	787.6M
Gross margin	42.7%	45.6%	43.2%	49%	45.7%	50.9%	52.6%	52.8%	55%	59%
Research & development	37.6M	39.2M	35.7M	30.9M	32.9M	46.8M	50.1M	54.4M	62.7M	59.8M
Selling, general & administrative	301.7M	316.5M	273.5M	282M	275.2M	340.1M	376.7M	431.8M	436.8M	442.4M
Operating expenses	339.3M	355.8M	309.2M	312.9M	308.1M	386.9M	426.8M	486.2M	499.5M	502.2M
Operating income	39.2M	56.2M	83.5M	145.9M	56.9M	71.1M	155.7M	173.3M	201.2M	241.4M
Operating margin	4.43%	6.21%	8.63%	14.8%	6.54%	7.16%	13.3%	13.2%	14.8%	18.1%
Non-operating income, net	-58.6M	8M	—	-42.5M	32.8M	9.6M	382K	-8.4M	20.6M	-84.7M
Pretax income	-27.5M	59.6M	73.6M	87.2M	72.9M	63.6M	141.4M	151.9M	212.1M	128M
Income tax	-1.2M	14.1M	18.6M	10.6M	-6.6M	20.3M	26M	34.3M	44.4M	30.7M
Net income	-26.3M	45.6M	55M	76.5M	79.5M	43.4M	115.4M	117.6M	167.7M	97.3M
Net margin	-2.96%	5.04%	5.69%	7.74%	9.13%	4.37%	9.87%	8.98%	12.3%	7.29%
EBITDA	128.9M	145.4M	193M	256.2M	141.2M	168.9M	249M	270.5M	316.8M	353.1M
EPS	-0.51	0.86	1.07	1.51	1.57	0.85	2.27	2.32	3.33	2.06
Diluted EPS	-0.51	0.85	1.04	1.48	1.55	0.84	2.24	2.29	3.31	2.05

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	Q3 26	Q4 26	Q1 27
Revenue	318.2M	336.3M	343.3M	336.2M	345.5M	348.5M	330.6M	321.4M	327.3M	339M	346.4M	339.4M
Cost of revenue	147.7M	158.4M	167.4M	161.2M	158.1M	155M	137.5M	129.2M	132.6M	136.6M	148.1M	136.6M
Gross profit	170.5M	177.9M	175.9M	174.9M	187.4M	193.5M	193.1M	192.2M	194.7M	202.4M	198.2M	202.8M
Gross margin	53.6%	52.9%	51.2%	52%	54.2%	55.5%	58.4%	59.8%	59.5%	59.7%	57.2%	59.8%
Research & development	12.7M	13.3M	15.9M	14.4M	16.5M	15.8M	15.9M	16.3M	14.9M	14.2M	14.4M	16.2M
Selling, general & administrative	115.3M	111.7M	121.7M	108.2M	106.9M	106.5M	115.1M	110.7M	101.6M	109.2M	120.9M	118.9M
Operating expenses	128M	125M	137.5M	122.7M	123.5M	122.3M	131.1M	127M	116.5M	123.3M	135.4M	135.1M
Operating income	35.3M	46M	27.9M	39.8M	51.7M	59M	50.7M	53.9M	67.1M	68.1M	52.3M	57.5M
Operating margin	11.1%	13.7%	8.14%	11.8%	15%	16.9%	15.3%	16.8%	20.5%	20.1%	15.1%	16.9%
Non-operating income, net	-10.4M	—	2M	—	—	—	—	—	-8.6M	-716K	-75.4M	—
Pretax income	32.8M	44M	23.4M	46.7M	44.7M	49.9M	70.7M	45.2M	51.3M	60M	-28.4M	47.6M
Income tax	7.9M	12.8M	3M	8.3M	10.9M	12.4M	12.8M	11.1M	12.6M	15.2M	-8.3M	14.6M
Net income	24.9M	31.2M	20.4M	38.4M	33.8M	37.5M	58M	34M	38.7M	44.7M	-20.1M	33M
Net margin	7.83%	9.29%	5.93%	11.4%	9.79%	10.8%	17.5%	10.6%	11.8%	13.2%	-5.82%	9.73%
EBITDA	58.3M	69.5M	55.6M	68.9M	80.9M	88.1M	99.5M	82.6M	95.3M	95.5M	79.7M	84.6M
EPS	0.49	0.62	0.4	0.75	0.66	0.75	1.18	0.71	0.81	0.96	-0.44	0.73
Diluted EPS	0.48	0.61	0.4	0.74	0.66	0.74	1.17	0.7	0.81	0.95	-0.44	0.72

P/E

Annual history by fiscal year; click a table row below to chart a different metric.

Current values are trailing twelve months where available, otherwise the latest fiscal year; unreported figures show a dash.

Key stats

Metric	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26	Current
Market cap	2.1B	3.9B	4.5B	5.1B	5.6B	3.2B	4.2B	4.3B	3.2B	2.7B	4.8B
Enterprise value	2.3B	3.9B	4.7B	5.4B	6.1B	3.7B	4.7B	5B	4.1B	3.6B	5.7B
Shares outstanding	51.5M	52.8M	51.5M	50.7M	50.7M	51M	50.8M	50.7M	50.3M	47.2M	47.2M

Valuation

Metric	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26	Current
P/E	—	84.7	81.9	66	70.8	74.4	36.4	36.8	19.1	27.3	50.9
P/S	2.36	4.27	4.66	5.11	6.46	3.25	3.6	3.31	2.35	1.99	3.54
P/B	2.83	5.13	6.75	8.6	7.69	4.31	5.14	4.51	3.9	3.34	5.72
EV/EBITDA	17.6	27	24.3	20.9	43.5	22.2	18.8	18.3	13	10.3	16
EV/Sales	2.56	4.35	4.85	5.42	7.07	3.77	4.01	3.79	3.03	2.73	4.25
Earnings yield	—	1.18%	1.22%	1.51%	1.41%	1.34%	2.75%	2.72%	5.24%	3.66%	1.97%
FCF yield	4%	3.77%	0.89%	2.17%	1.28%	2.35%	3.88%	2.67%	4.45%	9.79%	6.5%
PEG	—	—	—	—	—	—	—	—	—	—	17.7

Profitability

Metric	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26	Current
Gross margin	42.7%	45.6%	43.2%	49%	45.7%	50.9%	52.6%	52.8%	55%	59%	59.8%
Operating margin	4.43%	6.21%	8.63%	14.8%	6.54%	7.16%	13.3%	13.2%	14.8%	18.1%	17.9%
Net margin	-2.96%	5.04%	5.69%	7.74%	9.13%	4.37%	9.87%	8.98%	12.3%	7.29%	7.12%
ROE	-3.55%	6.06%	8.24%	13%	10.9%	5.79%	14.1%	12.2%	20.4%	12.2%	11.2%
ROA	-2.12%	3.68%	4.32%	6.04%	4.37%	2.33%	5.96%	5.35%	6.84%	4.06%	6.6%
ROIC	4.29%	5.2%	7.36%	14.4%	4.54%	3.84%	9.78%	8.44%	9.15%	10.3%	10.1%
Return on tangible assets	-5.69%	9.09%	9.2%	13.2%	50.9%	14.2%	25.6%	46.4%	50.7%	51.8%	52.7%

Financial health

Metric	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26	Current
Current ratio	2.42	1.35	2.44	2.2	2.74	1.71	3.06	2.56	1.62	2.95	3.08
Quick ratio	1.58	0.94	1.62	1.21	1.46	1.05	2.03	1.5	0.99	1.87	1.91
Debt / equity	0.43	0.34	0.52	0.75	0.98	1.03	0.94	0.84	1.49	1.54	1.4
Debt / assets	0.25	0.21	0.27	0.35	0.39	0.42	0.4	0.37	0.5	0.51	0.5
Net debt / EBITDA	1.36	0.51	0.94	1.19	3.7	3.04	1.93	2.33	2.9	2.77	2.68
Interest coverage	-2.39	14.2	8.43	6.38	5.33	4.72	10.7	12.7	22.8	5.46	5.36
Effective tax rate	0%	23.6%	25.3%	12.2%	0%	31.8%	18.4%	22.6%	20.9%	24%	26.2%

Per share

Metric	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26	Current
Revenue per share	17.2	17.1	18.8	19.5	17.2	19.5	23	25.8	27	28.3	29.1
EPS (basic)	-0.51	0.86	1.07	1.51	1.57	0.85	2.27	2.32	3.33	2.06	2.06
EPS (diluted)	-0.51	0.85	1.04	1.48	1.55	0.84	2.24	2.29	3.31	2.05	2.07
Book value per share	14.4	14.3	13	11.6	14.4	14.7	16.1	18.9	16.3	16.9	18.4
FCF per share	1.62	2.76	0.78	2.16	1.42	1.48	3.21	2.28	2.83	5.52	6.37
Cash per share	2.71	3.42	3.29	2.71	3.79	5.08	5.6	3.53	6.1	5.2	4.93
Capex per share	0.05	0.05	0.05	0.33	0.04	0.04	0.03	0.04	0.46	0.69	0.81

Capital allocation

Metric	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26	Current
Capex / revenue	0.32%	0.31%	0.29%	1.7%	0.21%	0.2%	0.14%	0.14%	1.71%	2.46%	2.73%
Capex / operating cash flow	5.64%	1.5%	2.31%	12.5%	1.06%	1.23%	0.7%	1.5%	10.9%	11.2%	11.3%
Payout ratio	—	—	—	—	—	—	—	—	—	—	0%

Period	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	Q3 26	Q4 26	Q1 27
Revenue	$318.2M	$336.3M	$343.3M	$336.2M	$345.5M	$348.5M	$330.6M	$321.4M	$327.3M	$339M	$346.4M	$339.4M
YoY change	+6.96%	+10.1%	+12.8%	+7.98%	+8.59%	+3.66%	-3.7%	-4.4%	-5.27%	-2.75%	+4.76%	+5.6%

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Cash & short-term investments	139.6M	180.2M	169.4M	137.3M	192.3M	259.5M	284.5M	178.8M	306.8M	245.4M
Receivables	152.7M	151.2M	185M	165.2M	127.6M	159.4M	179.1M	206.6M	202.7M	216.9M
Inventory	176.9M	160.8M	194.3M	270.3M	322.6M	293M	259.4M	317.2M	365.1M	306.4M
Total current assets	510M	521.2M	576.1M	603.6M	693.5M	756M	769.7M	768.9M	935M	834.9M
Property, plant & equipment	213.9M	217.5M	225.2M	152.1M	110.2M	154.1M	183.3M	187M	179M	196M
Goodwill & intangibles	776.8M	736M	677M	687.5M	1.7B	1.6B	1.5B	1.9B	2.1B	2.2B
Total assets	1.2B	1.2B	1.3B	1.3B	1.8B	1.9B	1.9B	2.2B	2.5B	2.4B
Accounts payable	43M	55.3M	63.4M	50.7M	50.3M	58.4M	63.9M	73.4M	67M	51.1M
Short-term debt	61M	194.3M	27.7M	84.3M	24.7M	214.1M	11.8M	10.2M	303.6M	5M
Total current liabilities	211.2M	384.7M	235.8M	274.8M	253.5M	442.3M	251.8M	300.4M	578.1M	282.6M
Long-term debt	253.6M	59.4M	322.5M	357.5M	690.6M	559.4M	754.1M	797.6M	921.2M	1.2B
Total liabilities	499.1M	484.9M	606.9M	680M	1.1B	1.1B	1.1B	1.2B	1.6B	1.6B
Shareholders' equity	739.6M	752.4M	667.9M	587.1M	731.7M	749.4M	818M	960M	820.8M	796.3M
Total debt	314.6M	253.7M	350.1M	441.8M	715.3M	773.6M	765.9M	807.8M	1.2B	1.2B
Net debt	175.1M	73.5M	180.8M	304.5M	523M	514.1M	481.4M	629M	918M	979.1M

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	Q3 26	Q4 26	Q1 27
Cash & short-term investments	—	—	—	—	—	—	—	—	296.4M	363.4M	245.4M	223.4M
Receivables	—	—	—	—	—	—	—	—	207.1M	195.7M	216.9M	216.1M
Inventory	—	—	—	—	—	—	—	—	336.2M	321.2M	306.4M	306.7M
Total current assets	—	—	—	—	—	—	—	—	899.7M	943.7M	834.9M	810.8M
Property, plant & equipment	—	—	—	—	—	—	—	—	182.9M	185.8M	196M	194M
Goodwill & intangibles	—	—	—	—	—	—	—	—	2.1B	2.1B	2.2B	2.2B
Total assets	—	—	—	—	—	—	—	—	2.4B	2.5B	2.4B	2.4B
Accounts payable	—	—	—	—	—	—	—	—	61.7M	48.7M	51.1M	56.3M
Short-term debt	—	—	—	—	—	—	—	—	304.3M	304.7M	5M	5M
Total current liabilities	—	—	—	—	—	—	—	—	548.3M	539.9M	282.6M	263.2M
Long-term debt	—	—	—	—	—	—	—	—	920.4M	920M	1.2B	1.2B
Total liabilities	—	—	—	—	—	—	—	—	1.6B	1.6B	1.6B	1.5B
Shareholders' equity	—	—	—	—	—	—	—	—	849.2M	911.5M	796.3M	837.1M
Total debt	—	—	—	—	—	—	—	—	1.2B	1.2B	1.2B	1.2B
Net debt	—	—	—	—	—	—	—	—	928.3M	861.4M	979.1M	950.8M

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Net income	-26.3M	45.6M	55M	76.5M	79.5M	43.4M	115.4M	117.6M	167.7M	97.3M
Depreciation & amortization	89.7M	89.2M	109.4M	110.3M	84.3M	97.7M	93.3M	97.2M	115.6M	111.7M
Stock-based compensation	9.2M	13M	17.2M	20.5M	25.5M	24.4M	25.6M	28.3M	29.6M	33.8M
Change in working capital	-16.6M	37.1M	-76.9M	-68.7M	562K	-25.7M	-16M	-118.3M	-83M	8.2M
Operating cash flow	50M	183.3M	121.9M	134.4M	172M	164.3M	230.7M	120.4M	214M	293.2M
Capital expenditure	2.8M	2.8M	2.8M	16.8M	1.8M	2M	1.6M	1.8M	23.3M	-32.8M
Investing cash flow	2.8M	11.8M	2.8M	-8.4M	-388.4M	10.2M	-33.6M	-240.5M	-105.5M	-144.9M
Dividends paid	—	—	—	—	—	—	—	—	—	—
Share repurchases	0	-100M	-160M	-175M	0	0	-75M	0	-225M	-175M
Financing cash flow	-93.4M	-161M	-64.1M	-143.2M	297.2M	-22.3M	-107.4M	30.9M	110.7M	-181.4M
Net change in cash	-40.6M	34.1M	60.6M	-17.2M	80.9M	152.1M	89.7M	-89.2M	219.3M	-33M
Free cash flow	83.6M	145.6M	40.3M	109.5M	71.8M	75.8M	162.9M	115.5M	142.4M	260.4M

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	Q3 26	Q4 26	Q1 27
Net income	24.9M	31.2M	20.4M	38.4M	33.8M	37.5M	58M	34M	38.7M	44.7M	-20.1M	33M
Depreciation & amortization	23M	23.5M	27.6M	29.1M	29.2M	29M	28.2M	28.8M	28.3M	27.4M	27.3M	27.1M
Stock-based compensation	6.7M	7.2M	7.4M	7.6M	6.9M	8.2M	6.9M	9.3M	7.6M	7.8M	9.1M	9.3M
Change in working capital	284K	-46M	-34.2M	-41.7M	-30.5M	-41M	20.5M	-10.9M	8.6M	20.3M	-9.8M	-13.5M
Operating cash flow	55.3M	13.8M	27.9M	24.1M	43.4M	38.3M	98.5M	17.4M	111.3M	93.6M	70.9M	52.3M
Capital expenditure	519K	338K	551K	20.4M	189K	251K	2.5M	-3.8M	-5M	-6.3M	-17.7M	-7.9M
Investing cash flow	-23M	-243.5M	2.1M	-133M	-14.5M	-8.8M	50.8M	-15.2M	-48.7M	-29.9M	-51.1M	-13.5M
Dividends paid	—	—	—	—	—	—	—	—	—	—	—	—
Share repurchases	—	0	0	—	—	0	-150M	—	—	0	-100M	—
Financing cash flow	-3.5M	216.6M	-69.5M	289M	-11K	-1.7M	-151.6M	-1.6M	-1.6M	-1.6M	-101.6M	-101.6M
Net change in cash	28.8M	-13.1M	-39.5M	180.2M	28.9M	27.7M	-2.3M	582K	61M	62.1M	-81.7M	-62.7M
Free cash flow	90M	-40.4M	54.4M	-33.1M	39.4M	35.2M	100.9M	13.6M	106.3M	87.2M	53.3M	44.4M

Haemonetics Corporation Financials

EPS

Revenue

Results

EPS

Revenue

Results

Total revenue

Total revenue

Revenue and profits

Condensed income statement

Revenue and profits

Condensed income statement

P/E

Key stats

Valuation

Profitability

Financial health

Per share

Capital allocation

Assets vs. liabilities & equity

Condensed balance sheet

Assets vs. liabilities & equity

Condensed balance sheet

Cash generation and uses

Condensed cash flow statement

Cash generation and uses

Condensed cash flow statement